title: Treatment of advanced non-small cell lung cancer (NSCLC): the "Umbria" cooperative study.
abstract: One hundred fifty-six patients with metastatic or locally advanced non-small cell lung cancer (NSCLC) were randomized to 3-week cycles of treatment with either: (A) cisplatin (120 mg/m2 on day 1); (B) cisplatin (120 mg/m2 on day 1) plus etoposide (VP-16) (100 mg/m2 on days 1-3; and (C) the cisplatin plus etoposide (VP-16) regimen plus mitomycin C (10 mg/m2 on days 1, 21, and 42; then every 6 weeks for a maximum dose of 100 mg). The overall objective response rates for the combination regimens (30% with two drugs and 26% with three drugs) were superior to that obtained with one drug (4%). Likewise, the median duration of survival with the combination therapy arms (8 to 9 months) was superior to that obtained with the single agent (5 months). Both performance status and limited disease were correlated with response in all groups, and with survival in the combined chemotherapy arms. The dose-limiting toxicity was myelosuppression, especially for the group receiving the three-drug regimen. In summary, combination chemotherapy using cisplatin and etoposide (VP-16) appears to be the most active and safest regimen in NSCLC.
authors.affiliation: Division of Medical Oncology, Policlinico Monteluce, Perugia, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Crinó
authors.forename: S
authors.initials: S
authors.lastname: Darwish
authors.forename: E
authors.initials: E
authors.lastname: Corgna
authors.forename: M L
authors.initials: ML
authors.lastname: Meacci
authors.forename: F
authors.initials: F
authors.lastname: Di Costanzo
authors.forename: F
authors.initials: F
authors.lastname: Buzzi
authors.forename: G
authors.initials: G
authors.lastname: Fornari
authors.forename: F
authors.initials: F
authors.lastname: Santi
authors.forename: E
authors.initials: E
authors.lastname: Ballatori
authors.forename: L
authors.initials: L
authors.lastname: Luccioli
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D009362:Neoplasm Metastasis; D011897:Random Allocation
chemical_list: D008937:Mitomycins; D016685:Mitomycin; D005047:Etoposide; D002945:Cisplatin